What was known before {#section20-2054358118760831}
=====================

Posttransplant lymphoproliferative disorder is a complication following kidney transplantation that can seriously threaten long-term outcomes, including overall patient and graft survival.

What this adds {#section21-2054358118760831}
==============

This research adds to the existing Canadian literature on the topic by presenting updated epidemiological data on posttransplant lymphoproliferative disorder in adult kidney transplant patients in British Columbia.

Introduction {#section22-2054358118760831}
============

Graft function and patient survival immediately following transplantation have improved dramatically since the early days of kidney transplantation, yet a number of complications still threaten long-term outcomes. Immunosuppression following transplantation is known to increase the risk of malignancy; posttransplant lymphoproliferative disorder (PTLD) is among the more common malignancies diagnosed.^[@bibr1-2054358118760831][@bibr2-2054358118760831]-[@bibr3-2054358118760831]^ Specifically, lymphoproliferative disorders occur greater than 10 times more frequently in kidney transplant recipients than in the general population.^[@bibr4-2054358118760831],[@bibr5-2054358118760831]^ PTLD is a heterogeneous disorder, ranging from very indolent to very aggressive.^[@bibr3-2054358118760831],[@bibr6-2054358118760831]^ Given this diversity, reported survival rates can be highly variable.^[@bibr1-2054358118760831]^ However, lymphomas in the aggregate have tended to be aggressive in nature and often poorly responsive to treatment, resulting in 5-year survival rates of less than 40%.^[@bibr7-2054358118760831]^

Treatment options for PTLD vary based on the disease subtype and may include rituximab monotherapy, rituximab with concurrent or sequential chemoimmunotherapy, radiation, or surgery.^[@bibr8-2054358118760831][@bibr9-2054358118760831][@bibr10-2054358118760831]-[@bibr11-2054358118760831]^ The almost universal initial step is the reduction in immunosuppression with the reported response rates ranging from 25% to 63%.^[@bibr12-2054358118760831]^ Balancing mortality risk with PTLD and risk of graft rejection in the setting of reduced immunosuppression is a challenge for clinicians.^[@bibr13-2054358118760831],[@bibr14-2054358118760831]^

In British Columbia (BC), the incidence of lymphoproliferative disorders following kidney transplant in a cohort of patients transplanted between 1986 and 1989 was last reported to be 1.26% in the late 1980s.^[@bibr15-2054358118760831]^ Since then, mycophenolate has largely replaced azathioprine as the antimetabolite of choice and, whenever possible, immunosuppression intensity has been reduced. Rapid steroid elimination protocols following kidney transplant have also since been incorporated into common practice. Whether these factors have any mediating effect on PTLD in this population is not known.

The purpose of this study was to characterize PTLD in kidney transplant patients in BC with regard to incidence, patient and graft survival, histological subtypes, treatment modalities, and management of immunosuppression.

Methods {#section23-2054358118760831}
=======

Study Population and Study Design {#section24-2054358118760831}
---------------------------------

This retrospective database study reviewed adult patients who underwent kidney transplantation in BC between 1996 and 2012. The study protocol was approved by the University of British Columbia Clinical Research Ethics Board and the Vancouver Coastal Health Research Institute. The institutional review bodies waived the need for informed consent.

A list of all patients who received a kidney transplant between January 1, 1996, and December 31, 2012, was generated from the clinical database of the provincial transplant agency (BC Transplant). The database includes transplant-related information on all renal transplant patients who have been seen by a transplant nephrologist in BC. This time period was selected to minimize confounding of PTLD incidence and survival by era of immunosuppression, as mycophenolate became the antimetabolite of choice in immunosuppressant protocols in BC starting in 1996. Patients less than 18 years of age at the time of first transplant and multiple organ transplant recipients were excluded from analysis.

To identify patients who developed PTLD, this list was cross-referenced with the British Columbia Cancer Agency (BCCA) registry of all patients with lymphoma diagnoses. The data in this registry are obtained from a population-based provincial arm of the Canadian national cancer registry, which is certified annually by the North American Association of Central Cancer Registries. Lymphoma diagnoses throughout the study period were coded according to World Health Organization (WHO) International Classification of Diseases for Oncology criteria by trained cancer registry abstractors. Data collection was completed via an electronic chart review. Patients were considered to have developed PTLD if the date of first kidney transplant preceded the date of lymphoma diagnosis. Patients were followed up for analysis of incident PTLD until December 31, 2012, and for outcomes of death and graft failure until December 31, 2014.

Statistical Analysis {#section25-2054358118760831}
--------------------

Continuous variables were analyzed using the *t* test for independent samples. Associations between categorical variables were tested for using the chi-square test and the Fisher exact test ([Table 1](#table1-2054358118760831){ref-type="table"}). Results were considered statistically significant if *P* values were \<.05. The aforementioned tests were conducted using XLSTAT Version 2016.05. Overall survival rates and graft survival were compared between PTLD and non-PTLD groups using Kaplan-Meier survival estimates ([Figures 1](#fig1-2054358118760831){ref-type="fig"} and [2](#fig2-2054358118760831){ref-type="fig"}). Patient survival was calculated from the date of transplant to the date of death by any cause or date of last follow-up. Graft survival was uncensored for death and calculated from the date of transplant to the date of graft failure or death. Fleming-Harrington and log-rank tests were used to compare survival distributions between PTLD and non-PTLD patients for patient and graft survival, respectively. Differences were determined to be statistically significant if *P* values were \<.05. Survival analyses were performed using RStudio version 0.99.903.

###### 

Demographic Data of Kidney Transplant Patients Who Developed PTLD (n = 37) and Those Who Did Not (n = 2180).

![](10.1177_2054358118760831-table1)

  ----------------------------------------------------------------------------------
  Characteristic                              PTLD (n = 37)\   No PTLD (n = 2180)\
                                              n (%)            n (%)
  ------------------------------------------- ---------------- ---------------------
  Male gender                                 24 (64.9)        1330 (61.0)

  Mean age at transplant, years (range)       46.6 (18-70)     49 (18-80)

  Mean age at PTLD diagnosis, years (range)   52.3 (19-78)     NA

  Ethnicity                                                    

   Caucasian                                  27 (73.0)        1437 (65.9)

   Asian                                      7 (18.9)         402 (18.4)

   Other                                      3 (8.1)          341 (15.6)

  Serology                                                     

   EBV mismatch                               6 (16.2)         100 (4.6)

   Presumed EBV mismatch                      2 (5.4)          25 (1.1)

  Induction therapy                                            

   Anti-IL-2-receptor antibodies              19 (51.4)        1259 (57.8)

   ATG                                        2 (5.4)          270 (12.4)

   OKT3                                       1 (2.7)          39 (1.8)

   None                                       15 (40.5)        612 (28.1)

  Prednisone Rx at discharge                  27 (73.0)        1281 (58.8)

  Donor type---deceased                       15 (40.5)        1032 (47.3)
  ----------------------------------------------------------------------------------

*Notes.* EBV serology categorized as "EBV mismatch" refers to cases in which the donor was EBV positive and the recipient EBV negative; "presumed EBV mismatch" refers to cases where no EBV serology data were available on the donor and the recipient was EBV negative. Induction therapy categorized as "none" refers to cases in which the patient did not receive ATG, OKT3, basiliximab, or daclizumab within the first 5 days post transplant. There were no significant differences between the groups. EBV = Epstein-Barr virus; PTLD = posttransplant lymphoproliferative disorder; ATG = antithymocyte globulin; OKT3 = muromonab-CD3; NA = not applicable.

![Kaplan-Meier survival analysis comparing overall survival from the time of transplant of patients who received at least 1 kidney transplant between January 1, 1996, and December 31, 2012, who went on to develop PTLD (n = 37) with patients who received a transplant during the same time period but did not develop PTLD (n = 2180).\
*Notes.* Overall survival was significantly worse in patients with PTLD compared with patients without PTLD (Fleming-Harrington test, *P* = .031). PTLD = posttransplant lymphoproliferative disorder.](10.1177_2054358118760831-fig1){#fig1-2054358118760831}

![Kaplan-Meier survival analysis comparing graft survival from the time of transplant, uncensored for death, of patients who received at least 1 kidney transplant between January 1, 1996, and December 31, 2012, who went on to develop PTLD (n = 37) with patients who received a transplant during the same time period but did not develop PTLD (n = 2180).\
*Notes.* Graft survival was significantly worse in patients with PTLD compared with patients without PTLD (log-rank test, *P* = .017). PTLD = posttransplant lymphoproliferative disorder.](10.1177_2054358118760831-fig2){#fig2-2054358118760831}

Results {#section26-2054358118760831}
=======

Of the 2217 adult patients identified by BC Transplant, 45 were identified by BCCA as also having lymphoma diagnoses within this time period. Of these patients, 7 had lymphoma diagnoses that predated their kidney transplants and did not go on to develop PTLD, and 1 patient's lymphoma diagnosis was an indolent small B-cell lymphoma. Thus, 37 of 2217 patients (1.7%) were found to have had PTLD diagnoses.

Demographic data of the 37 patients with PTLD and the 2180 patients who did not develop PTLD are summarized in [Table 1](#table1-2054358118760831){ref-type="table"}. Characteristics among the PTLD patients were not statistically different from the kidney transplant patients who did not develop PTLD. Time to PTLD diagnosis ranged from 2.9 to 166 months (median 63 months) post transplant; additional characteristics of the patients who developed PTLD are presented in [Table 2](#table2-2054358118760831){ref-type="table"}. Nine cases were early-onset PTLD; all others were considered late-onset cases. Of the early-onset cases, 6 were known or presumed to be EBV mismatched. Conversely, only 2 of 28 late-onset cases were EBV mismatched.

###### 

Characteristics of Kidney Transplant Patients With PTLD (n = 37).

![](10.1177_2054358118760831-table2)

  Patient ID   Gender   Ethnicity    Primary diagnosis                       Year of transplant   Age at transplant   Donor type   EBV status          Induction therapy   Age at PTLD diagnosis   Time to PTLD diagnosis (years)
  ------------ -------- ------------ --------------------------------------- -------------------- ------------------- ------------ ------------------- ------------------- ----------------------- --------------------------------
  1            F        Caucasian    Polycystic kidney disease               1997                 52                  NDD          No mismatch         OKT3                61                      9.25
  2            M        Caucasian    Polycystic kidney disease               2001                 59                  LD           No mismatch         None                67                      7.92
  3            M        Caucasian    Glomerulonephritis                      1998                 44                  LD           No mismatch         None                50                      6.83
  4            F        Caucasian    Polycystic kidney disease               2001                 62                  NDD          No mismatch         None                73                      11.5
  5            M        Caucasian    FSGS                                    2009                 49                  NDD          No mismatch         Basiliximab         52                      3.17
  6            M        Caucasian    T2DM                                    2003                 58                  LD           No mismatch         Basiliximab         66                      8.42
  7            M        Caucasian    Polycystic kidney disease               2002                 62                  NDD          No mismatch         Basiliximab         66                      4.58
  8            F        Asian        Lupus nephritis                         1999                 35                  LD           No mismatch         None                46                      11.5
  9            F        Caucasian    CKD, unknown etiology                   2006                 60                  LD           No mismatch         Basiliximab         63                      3.08
  10           M        Caucasian    Hypertension                            1998                 52                  NDD          No mismatch         None                65                      12.75
  11           M        Caucasian    Henoch-Schonlein purpura                1999                 25                  LD           Mismatch            None                26                      1.25
  12           M        Caucasian    FSGS                                    1998                 19                  LD           No mismatch         ATG                 22                      2.5
  13           F        Caucasian    FSGS                                    1999                 40                  LD           No mismatch         None                54                      13.75
  14           F        Asian        Lupus nephritis                         2003                 28                  NDD          No mismatch         Basiliximab         37                      8.58
  15           M        Asian        Hypertension                            2002                 42                  LD           No mismatch         Basiliximab         50                      8.33
  16           F        Asian        IgA nephropathy                         2007                 56                  LD           No mismatch         Basiliximab         61                      5.25
  17           F        Caucasian    T1DM                                    1998                 37                  NDD          Presumed mismatch   None                38                      0.75
  18           M        Caucasian    FSGS                                    1999                 34                  LD           Mismatch            None                43                      9.67
  19           M        Caucasian    Pyelonephritis/interstitial nephritis   2004                 18                  LD           Mismatch            Basiliximab         19                      1
  20           M        Asian        IgA nephropathy                         2001                 48                  LD           No mismatch         Basiliximab         55                      7
  21           M        Caucasian    Hypertension                            2010                 41                  LD           Mismatch            Basiliximab         42                      0.42
  22           M        Asian        IgA nephropathy                         1996                 33                  NDD          No mismatch         None                40                      7.42
  23           M        Asian        IgA nephropathy                         2001                 37                  LD           No mismatch         Basiliximab         45                      7.58
  24           M        Caucasian    T2DM                                    2006                 60                  NDD          No mismatch         Basiliximab         60                      0.33
  25           M        Caucasian    IgA nephropathy                         2003                 30                  LD           No mismatch         Basiliximab         39                      8.17
  26           M        Caucasian    Glomerulonephritis                      2000                 58                  LD           No mismatch         None                63                      5.17
  27           M        Caucasian    FSGS                                    2004                 50                  NDD          No mismatch         ATG                 51                      0.5
  28           F        Caucasian    Lupus nephritis                         1998                 55                  NDD          Presumed mismatch   None                56                      0.58
  29           F        Caucasian    CKD, unknown etiology                   2010                 51                  LD           Mismatch            Basiliximab         51                      0.42
  30           M        Aboriginal   Hypertension                            1999                 40                  NDD          No mismatch         None                52                      12.5
  31           M        Indian       Posterior urethral valves               2012                 21                  LD           Mismatch            Basiliximab         22                      0.25
  32           M        Caucasian    FSGS                                    2000                 70                  LD           No mismatch         None                78                      7.5
  33           M        Caucasian    Polycystic kidney disease               2009                 61                  LD           No mismatch         Basiliximab         62                      0.67
  34           F        Caucasian    Pyelonephritis/interstitial nephritis   2003                 61                  NDD          No mismatch         Basiliximab         66                      5.17
  35           F        Caucasian    CKD, unknown etiology                   2004                 67                  NDD          No mismatch         Basiliximab         70                      2.75
  36           M        Aboriginal   T2DM                                    1998                 60                  NDD          No mismatch         None                68                      7.75
  37           F        Caucasian    Glomerulonephritis                      2006                 51                  LD           No mismatch         Basiliximab         55                      3.92

*Notes.* PTLD = posttransplant lymphoproliferative disorder; EBV = Epstein-Barr virus; NDD = neurological determination of death; LD = living donor; OKT3 = muromonab-CD3; FSGS = focal segmental glomerulosclerosis; T2DM = type 2 diabetes mellitus; CKD = chronic kidney disease; ATG = antithymocyte globulin; IgA = immunoglobulin A; T1DM = type 1 diabetes mellitus; NA = not applicable. EBV serology categorized as "presumed mismatch" refers to cases where no EBV serology data were available on the donor and the recipient was EBV negative. Induction therapy categorized as "none" refers to cases in which the patient did not receive ATG, OKT3, basiliximab, or daclizumab within the first 5 days post transplant.

The primary sites, treatment modalities, and outcomes of patients with diffuse large B-cell lymphoma (DLBCL), polymorphic PTLD, and multiple myeloma are described in [Tables 3](#table3-2054358118760831){ref-type="table"}, [4](#table4-2054358118760831){ref-type="table"}, and [5](#table5-2054358118760831){ref-type="table"}, respectively. The same categories of information are presented for the patients with other types of PTLD in [Table 6](#table6-2054358118760831){ref-type="table"}. For most patients, PTLD management also included a reduction of immunosuppression.

###### 

Primary Site, Treatment, and Outcomes of Kidney Transplant Patients With DLBCL PTLD (n = 26).

![](10.1177_2054358118760831-table3)

  Patient ID   Pathology                       Primary site                          Treatment regimen                                                              Radiation   Surgery                        Outcome      Treatment of recurrence                   Time to death^[a](#table-fn4-2054358118760831){ref-type="table-fn"}^   Graft outcome                  Time to graft failure^[a](#table-fn4-2054358118760831){ref-type="table-fn"}^
  ------------ ------------------------------- ------------------------------------- ------------------------------------------------------------------------------ ----------- ------------------------------ ------------ ----------------------------------------- ---------------------------------------------------------------------- ------------------------------ ------------------------------------------------------------------------------
  1            Diffuse large B-cell lymphoma   Peritoneum                            Rituximab                                                                      No          No                             Death        NA                                        40                                                                     Failure prior to PTLD          NA
  2            Diffuse large B-cell lymphoma   Lymph nodes, intra-abdominal          Rituximab                                                                      No          No                             Death        NA                                        95                                                                     Death with functioning graft   95
  3            Diffuse large B-cell lymphoma   Liver                                 Rituximab                                                                      No          Adjuvant                       Recurrence   CHOP-R, R-ICE, BEAM                       1010                                                                   Failure                        980
  4            Diffuse large B-cell lymphoma   Lymph nodes                           Rituximab, then CHOP-R                                                         No          No                             Remission    NA                                        NA                                                                     Functioning graft              NA
  5            Diffuse large B-cell lymphoma   Lymph nodes, intra-abdominal          Modified CVP-R, 1st cycle IVAC, 2nd cycle modified CODOX-R, final cycle IVAC   No          No                             Remission    NA                                        NA                                                                     Functioning graft              NA
  6            Diffuse large B-cell lymphoma   Lymph nodes, multiple regions         None (palliative)                                                              No          No                             Death        NA                                        9                                                                      Death with functioning graft   9
  7            Diffuse large B-cell lymphoma   Lymph nodes, intra-abdominal          Prednisone, cyclophosphamide                                                   No          No                             Death        NA                                        31                                                                     Death with functioning graft   31
  8            Diffuse large B-cell lymphoma   Lymph nodes, intra-abdominal          CHOP-R                                                                         Yes         Adjuvant                       Recurrence   R-ICE, BEAM autograft, GDP-R, radiation   884                                                                    Death with functioning graft   884
  9            Diffuse large B-cell lymphoma   Lymph nodes, intra-abdominal          Rituximab, then CHOP-R                                                         No          No                             Remission    NA                                        NA                                                                     Functioning graft              NA
  10           Diffuse large B-cell lymphoma   Small intestine                       Rituximab                                                                      No          Yes (resection of intestine)   Remission    NA                                        NA                                                                     Functioning graft              NA
  11           Diffuse large B-cell lymphoma   Lymph nodes, intra-abdominal          Rituximab                                                                      No          No                             Remission    NA                                        NA                                                                     Functioning graft              NA
  12           Diffuse large B-cell lymphoma   Lymph nodes, intra-abdominal          Rituximab                                                                      No          No                             Remission    NA                                        NA                                                                     Failure                        638
  13           Diffuse large B-cell lymphoma   Lymph nodes of head, face, and neck   Rituximab                                                                      No          No                             Remission    NA                                        NA                                                                     Functioning graft              NA
  14           Diffuse large B-cell lymphoma   Lymph nodes                           Rituximab                                                                      No          No                             Remission    NA                                        NA                                                                     Functioning graft              NA
  15           Diffuse large B-cell lymphoma   Cecum                                 CHOP-R                                                                         No          No                             Remission    NA                                        NA                                                                     Functioning graft              NA
  16           Diffuse large B-cell lymphoma   Tonsil                                Rituximab, then CHOP-R                                                         No          No                             Remission    NA                                        NA                                                                     Functioning graft              NA
  17           Diffuse large B-cell lymphoma   Liver                                 Missing data                                                                   No          No                             Remission    NA                                        2894                                                                   Death with functioning graft   2894
  18           Diffuse large B-cell lymphoma   Small intestine                       Rituximab                                                                      No          Yes (resection of intestine)   Remission    NA                                        NA                                                                     Failure                        188
  19           Diffuse large B-cell lymphoma   Lymph nodes of head, face, and neck   Rituximab                                                                      No          No                             Remission    NA                                        NA                                                                     Functioning graft              NA
  20           Diffuse large B-cell lymphoma   Vertebrae                             CHOP-R                                                                         Yes         No                             Remission    NA                                        NA                                                                     Functioning graft              NA
  21           Diffuse large B-cell lymphoma   Lymph nodes, multiple regions         CHOP-R                                                                         No          No                             Remission    NA                                        NA                                                                     Functioning graft              NA
  22           Diffuse large B-cell lymphoma   Tonsil                                Rituximab                                                                      No          No                             Remission    NA                                        NA                                                                     Failure                        1587
  23           Diffuse large B-cell lymphoma   Liver                                 Rituximab + cyclophosphamide                                                   No          No                             Death        NA                                        13                                                                     Death with functioning graft   13
  24           Diffuse large B-cell lymphoma   Cecum                                 Rituximab                                                                      No          No                             Recurrence   Modified CHOP                             837                                                                    Death with functioning graft   837
  25           Diffuse large B-cell lymphoma   Lymph nodes, intra-abdominal          Rituximab, then CHOP-R                                                         No          No                             Remission    NA                                        NA                                                                     Functioning graft              NA
  26           Diffuse large B-cell lymphoma   Small intestine                       Rituximab                                                                      Yes         Yes (resection of intestine)   Recurrence   Cyclophosphamide and dexamethasone        1016                                                                   Death with functioning graft   1016

*Notes.* DLBCL = diffuse large B-cell lymphoma; PTLD = posttransplant lymphoproliferative disorder; CHOP = cyclophosphamide, doxorubicin, vincristine, prednisolone; CHOP-R = CHOP + rituximab; BEAM = carmustine, etoposide, cytarabine, melphalan; CVP-R = cyclophosphamide, vincristine, prednisolone, rituximab; IVAC = ifosfamide, etoposide, cytarabine; modified CODOX-R = cyclophosphamide, vincristine, doxorubicin, rituximab; R-ICE = rituximab, ifosfamide, carboplatin, etoposide; GDP-R = gemcitabine, dexamethasone, cisplatin, rituximab; NA = not applicable.

From PTLD diagnosis (days).

###### 

Primary Site, Treatment, and Outcomes of Kidney Transplant Patients With Polymorphic PTLD (n = 5).

![](10.1177_2054358118760831-table4)

  Patient ID   Pathology          Primary site                          Treatment regimen   Radiation   Surgery                        Outcome     Time to death^[a](#table-fn6-2054358118760831){ref-type="table-fn"}^   Graft outcome                  Time to graft failure^[a](#table-fn6-2054358118760831){ref-type="table-fn"}^
  ------------ ------------------ ------------------------------------- ------------------- ----------- ------------------------------ ----------- ---------------------------------------------------------------------- ------------------------------ ------------------------------------------------------------------------------
  27           Polymorphic PTLD   Liver                                 Rituximab           No          No                             Remission   NA                                                                     Failure                        574
  28           Polymorphic PTLD   Lymph nodes of head, face, and neck   None                Yes         No                             Remission   2207                                                                   Death with functioning graft   2207
  29           Polymorphic PTLD   Lymph nodes                           Rituximab           No          No                             Remission   NA                                                                     Failure                        38
  30           Polymorphic PTLD   Lymph nodes, intra-abdominal          Rituximab           No          Yes (resection of intestine)   Remission   NA                                                                     Functioning graft              NA
  31           Polymorphic PTLD   Lymph nodes of head, face, and neck   Rituximab           No          No                             Remission   NA                                                                     Functioning graft              NA

*Notes.* PTLD = posttransplant lymphoproliferative disorder; NA = not applicable.

From PTLD diagnosis (days).

###### 

Treatment and Outcomes of Patients With Multiple Myeloma Following Kidney Transplant (n = 4).

![](10.1177_2054358118760831-table5)

  Patient ID   Pathology          Treatment regimen                  Radiation   Surgery   Outcome          Time to death^[a](#table-fn8-2054358118760831){ref-type="table-fn"}^   Graft outcome                  Time to graft failure^[a](#table-fn8-2054358118760831){ref-type="table-fn"}^
  ------------ ------------------ ---------------------------------- ----------- --------- ---------------- ---------------------------------------------------------------------- ------------------------------ ------------------------------------------------------------------------------
  32           Multiple myeloma   None (palliative)                  Yes         No        Death            159                                                                    Failure prior to PTLD          NA
  33           Multiple myeloma   None (conservative surveillance)   No          No        Stable myeloma   NA                                                                     Functioning graft              NA
  34           Multiple myeloma   Melphalan and prednisone           No          No        Death            493                                                                    Death with functioning graft   493
  35           Multiple myeloma   Missing data                       No          No        Death            46                                                                     Failure prior to PTLD          NA

*Notes.* PTLD = posttransplant lymphoproliferative disorder; NA = not applicable.

From PTLD diagnosis (days).

###### 

Primary site, Treatment, and Outcomes of Kidney Transplant Patients With PTLD, Subtype Other Than Those in [Tables 1](#table1-2054358118760831){ref-type="table"} to [3](#table3-2054358118760831){ref-type="table"} (n = 2).

![](10.1177_2054358118760831-table6)

  Patient ID   Pathology                                             Primary site                                    Treatment regimen                             Radiation   Surgery   Outcome     Time to death^[a](#table-fn10-2054358118760831){ref-type="table-fn"}^   Graft outcome                  Time to graft failure^[a](#table-fn10-2054358118760831){ref-type="table-fn"}^
  ------------ ----------------------------------------------------- ----------------------------------------------- --------------------------------------------- ----------- --------- ----------- ----------------------------------------------------------------------- ------------------------------ -------------------------------------------------------------------------------
  36           Plasmacytoma                                          Rib, sternum, clavicle, and associated joints   None (palliative)                             No          No        Death       49                                                                      Death with functioning graft   49
  37           Exact diagnosis unknown (DLBCL vs Burkitt lymphoma)   Peritoneum                                      Hydrocortisone, prednisone, CODOX-M, IVAC-R   No          No        Remission   NA                                                                      Functioning graft              NA

*Notes.* PTLD = posttransplant lymphoproliferative disorder; DLBCL = diffuse large B-cell lymphoma; CODOX-M = cyclophosphamide, vincristine, doxorubicin, methotrexate; IVAC-R = ifosfamide, etoposide, cytarabine, rituximab; NA = not applicable.

From PTLD diagnosis (days).

Twenty-six patients developed DLBCL, of which 23 patients were treated with rituximab. Of the patients treated with rituximab, 13 received rituximab monotherapy, and 10 received rituximab in combination with chemotherapy, with the most common chemotherapy regimen being CHOP-R. Among the patients who received rituximab, 16 achieved remission without recurrence ([Table 3](#table3-2054358118760831){ref-type="table"}).

Among all PTLD patients, the 1- and 2-year patient survival rates were 78.4% and 75.7%, respectively. Survival was excellent among early-onset cases, with 100% surviving to 2 years post diagnosis of PTLD. Survival among late-onset PTLD patients was less favorable, with 1- and 2-year survival rates being 71.4% and 67.9%, respectively. Overall survival was significantly worse in patients with PTLD than in kidney transplant patients who did not develop PTLD (Fleming-Harrington, *P* = .031; [Figure 1](#fig1-2054358118760831){ref-type="fig"}). Overall graft survival, uncensored for death, was also significantly worse in patients with PTLD than in patients without (log-rank test, *P* = .017). Median graft survival was 9.5 years among patients with PTLD and 16 years among patients without ([Figure 2](#fig2-2054358118760831){ref-type="fig"}).

Discussion {#section27-2054358118760831}
==========

This study is the most recent update on incidence, characteristics, and outcomes of PTLD in BC kidney transplant patients since the 1980s.^[@bibr15-2054358118760831]^ Changes in immunosuppression protocols that have occurred since this time had the potential to alter the frequency with which PTLD was occurring.

PTLD occurred in 1.7% of patients who received kidney transplants between 1996 and 2012 in BC, which is consistent with the range of 1% to 2% that has been reported in the literature.^[@bibr1-2054358118760831],[@bibr7-2054358118760831],[@bibr16-2054358118760831][@bibr17-2054358118760831]-[@bibr18-2054358118760831]^ This incidence is not appreciably different from the 6 lymphoma cases Melosky et al reported out of the 478 kidney transplant patients studied between 1986 and 1989.^[@bibr15-2054358118760831]^ However, Melosky et al followed patients for a mean period of only 26 months, implying a number of late-onset cases were likely not captured, and that the true frequency of PTLD may have been higher than what was reported. Other Canadian literature reports that 2.5% of kidney transplant patients during this period were affected by early-onset PTLD.^[@bibr19-2054358118760831]^ Considering lymphomas affect kidney transplant patients at significantly higher rates than they do the general population, the frequency of PTLD among kidney transplant patients in BC, while low, remains a concerning cause of morbidity and mortality among this population.

Several studies have identified risk factors for the development of PTLD following solid organ transplantation. Among these include EBV seronegativity of recipient, Caucasian ethnicity, male gender, and age less than 18 years.^[@bibr3-2054358118760831],[@bibr10-2054358118760831],[@bibr20-2054358118760831][@bibr21-2054358118760831][@bibr22-2054358118760831]-[@bibr23-2054358118760831]^ Some of these are additive, with young Caucasian males being among the highest risk of developing PTLD.^[@bibr20-2054358118760831],[@bibr24-2054358118760831]^ Our study appears to corroborate some of this research, as 21.6% of patients with PTLD were EBV negative (documented as either EBV mismatch or, when EBV serology data were unavailable for the donor, presumed EBV mismatch) compared with only 5.7% of patients who did not develop PTLD. Although not statistically significant, there were also a greater proportion of patients who were Caucasian (73.0% vs 65.9%) and male (64.9% vs 61.0%) in the PTLD group as compared with the non-PTLD group. The majority of reported PTLD cases are associated with EBV.^[@bibr25-2054358118760831],[@bibr26-2054358118760831]^ Therefore, the degree of immunosuppression received is an important risk factor for the development of PTLD as it influences the body's response to EBV.^[@bibr21-2054358118760831],[@bibr22-2054358118760831],[@bibr27-2054358118760831][@bibr28-2054358118760831]-[@bibr29-2054358118760831]^ In a study of over 145 000 cadaver kidney transplant recipients, OKT3 and ATG exposure were associated with a 3- to 4-fold higher incidence of PTLD, whereas anti-IL-2-receptor antibodies were not associated with an increased incidence of PTLD.^[@bibr30-2054358118760831]^ Interestingly, a greater proportion of PTLD patients (40.5% vs 28.1% of non-PTLD patients) in this study did not receive induction therapy with ATG, OKT3, basiliximab, or daclizumab within the first 5 days post transplant. Similarly, smaller proportions of PTLD patients received either anti-IL-2-receptor antibodies (51.4% vs 57.8% of non-PTLD patients) or ATG (5.4% vs 12.4% of non-PTLD patients) for induction therapy. As hypothesized, our PTLD population did consist of a greater proportion of patients (2.7% vs 1.8% of non-PTLD patients) who had received OKT3 induction therapy. Maintenance immunosuppression of individual patients was not examined in detail in this study; the evidence implicating individual maintenance immunosuppressant agents is conflicting and appears to suggest that the net effect of immunosuppression regimens post transplantation, not a particular individual agent, is more associated with the risk of PTLD.^[@bibr31-2054358118760831]^ Duration of immunosuppression therapy, a known risk factor for the development of late-onset PTLD,^[@bibr10-2054358118760831]^ was also not captured by these data.

Both adult kidney transplant programs in BC have utilized rapid steroid elimination protocols since 2003. It has been reported that steroid maintenance therapy is associated with a decreased risk of developing late-onset PTLD^[@bibr3-2054358118760831]^; however, other sources suggest that steroid-free protocols do not alter the frequency with which PTLD occurs.^[@bibr18-2054358118760831],[@bibr32-2054358118760831]^ The overall 1.7% incidence of PTLD in our kidney transplant patients was consistent with other studies that did not specify the use of rapid steroid elimination protocols.^[@bibr7-2054358118760831],[@bibr16-2054358118760831]^ Given the nature of the study design, our results permit the ability to merely speculate on the effect that rapid steroid elimination may have on the risk of PTLD. In addition, the ability to capture the degree to which, if any, steroids mitigate or propagate the risk of PTLD following kidney transplantation is challenged because of other concomitant changes to immunosuppression regimens that have likely had greater bearing on the risk of PTLD.

PTLD management varies based on the subtype; however, a nearly universal initial step is reduction in immunosuppression.^[@bibr1-2054358118760831],[@bibr10-2054358118760831],[@bibr11-2054358118760831],[@bibr13-2054358118760831]^ The majority of our patients underwent a reduction of immunosuppression upon PTLD diagnosis; however, the degree of reduction was not studied.

In patients who fail to adequately respond to a reduction of immunosuppression, treatment options for patients with monomorphic or systemic polymorphic PTLD may include rituximab with or without chemoimmunotherapy.^[@bibr11-2054358118760831]^ Rituximab, an anti-CD20 monoclonal antibody not associated with treatment-related mortality, is frequently used as monotherapy after lack of response from a reduction in immunosuppression alone, or in simultaneous or sequential combination with CHOP.^[@bibr9-2054358118760831],[@bibr16-2054358118760831],[@bibr27-2054358118760831],[@bibr33-2054358118760831],[@bibr34-2054358118760831]^ Previously, CHOP and CHOP-R were reported to have a 31% treatment-associated mortality in immunosuppressed patients.^[@bibr33-2054358118760831]^ However, a more recent B-cell PTLD treatment trial reported that sequential treatment with rituximab followed by CHOP chemotherapy was associated with a much lower (11%) risk of treatment-related mortality.^[@bibr9-2054358118760831]^

Of the 26 DLBCL patients, 23 were treated with rituximab, either alone or in combination with CHOP or CHOP-like chemotherapy. Supporting the notion that rituximab is a mainstay of therapy for a number of PTLD subtypes, outcomes were favorable for the majority of patients treated with rituximab, as 16 of the 23 patients treated with rituximab (69.6%) achieved remission without recurrence. Recurrence occurred in 4 patients, which may be a consequence of rituximab not altering cellular immune response to EBV, thereby not offering a long-term defense against EBV-positive B-cell proliferation once B-cell recovery following rituximab therapy occurs.^[@bibr12-2054358118760831]^ The recurrence rate seen following monotherapy with rituximab in BC is lower than that which has been observed in rituximab monotherapy prospective studies.^[@bibr9-2054358118760831]^

Given the heterogeneity of disorders categorized as PTLD, prognosis can be highly variable. A number of factors have been reported to negatively influence a patient's prognosis, including late-onset PTLD, advanced age at diagnosis, central nervous system (CNS) involvement, monomorphic PTLD, T-cell PTLD, poor performance status, extranodal disease, and renal insufficiency.^[@bibr35-2054358118760831][@bibr36-2054358118760831][@bibr37-2054358118760831][@bibr38-2054358118760831][@bibr39-2054358118760831][@bibr40-2054358118760831]-[@bibr41-2054358118760831]^ Our data correspond with some of these prognostic factors. Late-onset cases fared worse, with 1- and 2-year survival rates of 71.4% and 67.9% in the late-onset group compared with 100% survival at 2 years in the early-onset group. Late-onset PTLD is more likely to be EBV negative, which has been associated with worse outcomes.^[@bibr10-2054358118760831],[@bibr42-2054358118760831]^ These findings are in contrast to results from studies reporting no difference in survival between patients with early-onset and late-onset PTLD.^[@bibr8-2054358118760831],[@bibr30-2054358118760831]^

The overall 1- and 2-year survival rates of the 37 patients diagnosed with PTLD in BC were 78.4% and 75.7%, respectively. Our overall survival data do not appear worse than what has been reported by other retrospective database studies, with 5-year survival rates among kidney transplant patients with PTLD being between 53% and 64%.^[@bibr39-2054358118760831],[@bibr43-2054358118760831]^ Outcomes of PTLD following kidney transplant in BC appear better in today's era of immunosuppression than they did in the 1980s, but previous data do not specify specific survival rates. Melosky and colleagues identified 6 patients with PTLD following kidney transplant; there were no survivors among the 5 patients diagnosed with non-Hodgkin lymphoma.^[@bibr15-2054358118760831]^ The outcome of the sixth patient, diagnosed with Hodgkin's lymphoma, was not specified.

The ability to accurately capture all cases of PTLD in a population is threatened by a number of factors, most notably the potential loss to follow-up of patients who develop late-onset PTLD and the possible omission of PTLD documentation in clinic records. One of this study's strengths is that it incorporated data from both a provincial transplant database and a provincial cancer database, increasing the likelihood that all PTLD cases were captured. Limitations to this study inherent to its design include its retrospective nature, the unknown adherence to prescribed immunosuppressants, and the reduced follow-up for patients transplanted in the latter years of the time period studied. The degree of immunosuppression reduction for PTLD management was not effectively captured, nor were cumulative doses of immunosuppression, including immunosuppression used for the treatment of rejection. Furthermore, database standards were not consistent over the time period studied, limiting the quality and quantity of data that could be retrieved.

Conclusion {#section28-2054358118760831}
==========

This study suggests the rate of PTLD in BC following kidney transplantation is low and consistent with rates reported in literature. The incidence of late-onset PTLD and its association with reduced patient and graft survival warrant further analysis of patients' long-term immunosuppression and ongoing surveillance for the development of PTLD. Further research should focus on the treatment of PTLD, particularly given the associations between late-onset PTLD and reduced patient and graft survival.
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